1 / 17

European Clinical Trial Directive (Directive 2001/20/EC)

European Clinical Trial Directive (Directive 2001/20/EC). dr. Cees Smit (NPCF/EGAN) EPF Annual Meeting May 19, Brussels. European Clinical Trial Directive. 1998/1999 Concerns expressed by European Patient Organisations Recommendation: one European research/registration file

hue
Download Presentation

European Clinical Trial Directive (Directive 2001/20/EC)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. European Clinical Trial Directive(Directive 2001/20/EC) dr. Cees Smit (NPCF/EGAN) EPF Annual Meeting May 19, Brussels

  2. European Clinical Trial Directive 1998/1999 • Concerns expressed by European Patient Organisations • Recommendation: one European research/registration file 2004 – 2006: Implementation at MS level 2007 (Evaluation EU/EMEA October 3, 2007, London) • More paper work, bureaucracy • 1 Directive, 27 Member States Implementations • Less research, less academic research • Higher prices, higher insurance premiums, • Less research money/grants • Patients not represented in Research Ethic Committees

  3. The current situation • Numerous articles and case-studies have postulated that Directive 2001/20/EC, the ‘Clinical Trial Directive’ has failed to promote efficient clinical research in Europe and to better protect the study participants • However, there are more causes for the decreasing clinical research activity in Europe (if so!) than the legal framework alone • Consultation EC end 2009, response EPF

  4. Response EPF January 19, 2010 (1) • Questionnaire EC highly technical • The effectiveness of clinical trials throughout the EU is of fundamental importance for EPF and its members. • EPF and its members very active in this area: • So input drawn on evidence from Value+, • PatientPartner (VSOP, EGAN, EFGCP), Involve, Respect, EMA/EPF, Europa Donna, IDF-EU

  5. Response EPF January 19, 2010 (2) • Meaningful patients’ involvement in clinical trials processes (Eurordis charter OD) • Access to quality information at all stages • Informed consent in an accessible language • Clinical trials for paediatric patients • Transparancy regarding clinical trials across EU incl. learning from trials that have failed • Access to treatment after the trial

  6. Response EPF January 19, 2010 (3) • Finally, EPF welcomes the Commission’s initiative to consult the public on the Directive • EPF is committed to work with the Commission and other relevant stakeholders in translating the vision and the core issues outlined in their response into more effective, patient-centred EU legislation on clinical trials

  7. Commissioner John Dalli • Recently told the Parliament that the Clinical Trials Directive is going to be reopened, but it is not clear yet whether it will be a light revision of the text or a full revision of the text. • A first draft is expected by Winter 2011

  8. Drug development process End of patent Patent request effective patent-period clinical research fundamental pre-clinical research Ph. 1 Phase 3 Phase 4 Phase 2 post marketing research Registration launch product 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 JR 2005 YearsRef: Jan Raaijmakers (2005, UU)

  9. The theory: levels of patient participation in clinical research ref: www.patientpartner-europe.eu Drivingforce Co-researcher Reviewer Advisor Information provider Research subject 9 11/03/2014

  10. Outcome PatientPartner survey DrivingForce Co-researcher Reviewer Advisor Information Provider Research subject 10 11/03/2014

  11. www.eurordis.org Role of Patient Groups in Research and their Priorities for the Future Fabrizia Bignami Eurordis Therapeutic Development Director Rare Disease Day Workshop Brussels, 1 March 2010

  12. 37% of POs financially support research Multisyst Neurology Dermato >75% 60-75% Musculosk Ophthalmo Metabolic 45-60% 30-45% Neuromusc Oncology Cardiovasc 15-30% <15% Haemato Others Umbrella Distribution by disease type Distribution by country

  13. What kind of research do patients fund? 81 % Basic research 57% Therapeutics 56% Diagnosis 54% Epidemiology / Natural history of the disease 46% Human and Social Science 24% Assistance technologies / Daily life 19% Research infrastructures

  14. Development costs of a new drug

  15. The ‘productivity’ gap • Input: $ 50 – 80 miljard R&D spending/year • Output: 5 – 6 ‘first in class’ drugs/year • Payers/HTA adding C + E criteria further reduce the number of products that will reach the patient (Hans-Georg Eichler, TI Pharma, April 28, 2010)

  16. For further information smit.visch@wolmail.nl

More Related